NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/13/2023
Back to search
Official data from USPTO
HEMEWISE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
03/13/2023
Trademark type
Word
Nice classes
5, 44
Filing date
12/15/2020
Registration date
05/24/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/24/2022
Last transaction
05/24/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
JP
Examiner
BURDECKI, ANNA C
Law office
L80
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Otsuka Pharmaceutical Co., Ltd.
Representatives
Kazuyo Morita Holland & Hart LLP
Technical classification
Nice Classes
Class 5Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Diagnostic preparations for medical purposes excluding the diagnosis and treatment of hemophilia; diagnostic reagents for medical use excluding the diagnosis and treatment of hemophilia
Class 44
Medical diagnostic services in the nature of performing diagnosis of disease excluding hemophilia; medical testing for diagnostic or treatment purposes excluding hemophilia
Publications
History of USPTO decisions and trademark events.
31 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/02/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/08/2022
FIMP
FINAL DISPOSITION PROCESSED
09/08/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
08/24/2022
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/24/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
05/24/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/08/2022
PUBO
PUBLISHED FOR OPPOSITION
03/08/2022
GPNX
NOTIFICATION PROCESSED BY IB
03/07/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/16/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
02/16/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/16/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/28/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
01/28/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/28/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
01/28/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/28/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/24/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/24/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/24/2021
RFNT
REFUSAL PROCESSED BY IB
07/11/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/24/2021
RFRR
REFUSAL PROCESSED BY MPU
06/24/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/16/2021
CNRT
NON-FINAL ACTION WRITTEN
06/15/2021
DOCK
ASSIGNED TO EXAMINER
06/02/2021
MAFR
APPLICATION FILING RECEIPT MAILED
03/16/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/12/2021
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
03/11/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/04/2021
Continuous trademark protection
Get notified about every new filing that threatens HEMEWISE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.